Sam North
Education
Royal Australian Navy - 👉 Bachelor of Electronic and Communications Engineering
Written For
Releaf, High Times, Cookies Seeds, Cannabis Now Magazine, Fast Buds, MSNL, Paradise Seeds, Cookies Seeds, Premium Cultivars
Sam North is a content, SEO, and growth strategist at Releaf, specialising in medical cannabis, digital health, and patient education within a UK regulatory framework. After a decade immersed in the cultivation side of the cannabis industry, Sam moved into digital in 2020. He worked across the recreational space with seed companies, CBD brands, and cannabis publications, before transitioning into the medical cannabis sector in early 2023 and joining Releaf in April of that year. Today, his work spans both content and SEO, with a focus on how the two support patient understanding and long-term organic growth. He writes and shapes educational content, research breakdowns, and patient-facing web copy, ensuring it is clear, clinically accurate, and aligned with UK compliance requirements. Alongside this, he contributes to broader SEO and content strategy, owning projects across search performance, content direction, and site optimisation. His work focuses on identifying growth opportunities, refining structure, and improving how content is discovered and performs in search. At Releaf, Sam’s focus is on making medical cannabis more understandable and accessible to patients, while maintaining a high standard of accuracy, compliance, and trust.
Releaf articles
Decoding Cannabis: what the first placebo-controlled cannabis migraine trial means for patients in 2026
The first randomised, placebo-controlled trial of vaporised cannabis for migraine attacks has finally been published. Researchers at UC San Diego compared THC, CBD, a balanced combination, and placebo across 247 treated migraines. The balanced ratio came out clearly ahead, with sustained benefit at 24 and 48 hours and no serious adverse events. We unpack what the trial proves, where it falls short, and how the results sit alongside Releaf's UK patient survey data on medical cannabis for migraine.
What the UK’s largest active medical cannabis patient survey revealed about gastroenterological conditions
96.1% of UK gastroenterological patients surveyed in Releaf’s 2025 medical cannabis survey said their prescribed medical cannabis treatment was effective at managing their symptoms, 97.4% reported improvements in their overall quality of life, and 98.7% said they would recommend medical cannabis treatment to someone with a similar qualifying condition.
94.4% of patients with sleep conditions report effective treatment: results from the UK’s largest medical cannabis survey
Based on UK patient data from 329 respondents within a wider survey of 1,669 participants, 94.4% say medical cannabis is effective for sleep-related conditions, with 82% noticing changes within the first week and 97.9% experiencing improved quality of life. The findings come from the largest ever survey of active UK medical cannabis patients.